842131-33-3
Chemical Structure
Ulimorelin
Synonym(s): TZP-101
- CAS No.: 842131-33-3
- Formula:C30H39FN4O4
- Molecular Weight:538.65
IUPAC Name: (2R,5S,8R,11R)-5-cyclopropyl-11-(4-fluorobenzyl)-2,7,8-trimethyl-4,5,7,8,10,11,13,14,15,16-decahydro-2H-benzo[q][1]oxa[4,7,10,13]tetraazacyclooctadecine-6,9,12(3H)-trione
InChIKey: WGYPAJVJMXQXTR-ABNZCKJZSA-N
SMILES: O=C(N(C)[C@H](C)C(N[C@@H]1CC2=CC=C(F)C=C2)=O)[C@H](C3CC3)NC[C@@H](C)OC4=CC=CC=C4CCCNC1=O
Biological Activity: Ulimorelin (TZP-101) is a ghrelin receptor (GRLN) agonist with an EC50 of 29 nM and a Ki of 16 nM. Ulimorelin is a prokinetic agent and causes vasorelaxation through competitive antagonist action at α1-adrenoceptors. Ulimorelin stimulates intestinal motility and is used for malnutrition[1][2][3].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ulimorelin | 96.10% | Ulimorelin (TZP-101) is a ghrelin receptor (GRLN) agonist with an EC50 of 29 nM and a Ki of 16 nM. Ulimorelin is a prokinetic agent and causes vasorelaxation through competitive antagonist action at α1-adrenoceptors. Ulimorelin stimulates intestinal motility and is used for malnutrition. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.52
HY-129642Hirsutide -
Similarity Score 0.51
HY-N14928Phepropeptin B -
Similarity Score 0.51
HY-P11335Oscillamide Y -
Similarity Score 0.50
HY-P2209Nummularine B -
Similarity Score 0.50
HY-N14940Phepropeptin D -
Similarity Score 0.49
HY-P11451Pentixafor peptide cyclo(dTyr-dOrn(NMe)-R-Nal-G) -
Similarity Score 0.49
HY-P6294Pseudostellarin G -
Similarity Score 0.49
HY-115761Dihydrochlamydocin -
Similarity Score 0.49
HY-P3316OSK-1 -
Explore the MedChemAI to find more analogs
References
- [1]. Pustovit RV, et al. The mechanism of enhanced defecation caused by the ghrelin receptor agonist, ulimorelin. Neurogastroenterol Motil. 2014 Feb;26(2):264-71. [Content Brief]
- [2]. Broad J, et al. Analysis of the ghrelin receptor-independent vascular actions of ulimorelin. Eur J Pharmacol. 2015 Apr 5;752:34-9. [Content Brief]
- [3]. Hoveyda HR, et al. Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I): Development of ulimorelin (TZP-101) from hit to clinic. J Med Chem. 2011 Dec 22;54(24):8305-20. [Content Brief]
